ID   ZBT7A_HUMAN             Reviewed;         584 AA.
AC   O95365; D6W619; O00456; Q14D41; Q5XG86;
DT   13-APR-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   28-JUN-2023, entry version 204.
DE   RecName: Full=Zinc finger and BTB domain-containing protein 7A {ECO:0000305};
DE   AltName: Full=Factor binding IST protein 1 {ECO:0000303|PubMed:9973611};
DE            Short=FBI-1 {ECO:0000303|PubMed:9973611};
DE   AltName: Full=Factor that binds to inducer of short transcripts protein 1;
DE   AltName: Full=HIV-1 1st-binding protein 1;
DE   AltName: Full=Leukemia/lymphoma-related factor {ECO:0000303|PubMed:9927193};
DE   AltName: Full=POZ and Krueppel erythroid myeloid ontogenic factor {ECO:0000303|PubMed:15662416};
DE            Short=POK erythroid myeloid ontogenic factor {ECO:0000303|PubMed:15662416};
DE            Short=Pokemon {ECO:0000303|PubMed:15662416};
DE            Short=Pokemon 1 {ECO:0000303|PubMed:17595526};
DE   AltName: Full=TTF-I-interacting peptide 21 {ECO:0000312|EMBL:AAB58414.1};
DE            Short=TIP21 {ECO:0000312|EMBL:AAB58414.1};
DE   AltName: Full=Zinc finger protein 857A;
GN   Name=ZBTB7A {ECO:0000312|HGNC:HGNC:18078};
GN   Synonyms=FBI1, LRF {ECO:0000303|PubMed:9927193}, ZBTB7
GN   {ECO:0000312|HGNC:HGNC:18078}, ZNF857A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND SUBUNIT.
RC   TISSUE=Carcinoma;
RX   PubMed=9973611; DOI=10.1093/nar/27.5.1251;
RA   Morrison D.J., Pendergrast P.S., Stavropoulos P., Colmenares S.U.,
RA   Kobayashi R., Hernandez N.;
RT   "FBI-1, a factor that binds to the HIV-1 inducer of short transcripts
RT   (IST), is a POZ domain protein.";
RL   Nucleic Acids Res. 27:1251-1262(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lung;
RA   Jansa P., Grummt I.;
RT   "cDNA encoding TTF-I interacting peptide 21 (TIP21).";
RL   Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   TISSUE SPECIFICITY.
RX   PubMed=9927193; DOI=10.1038/sj.onc.1202332;
RA   Davies J.M., Hawe N., Kabarowski J., Huang Q.-H., Zhu J., Brand N.J.,
RA   Leprince D., Dhordain P., Cook M., Moriss-Kay G., Zelent A.;
RT   "Novel BTB/POZ domain zinc-finger protein, LRF, is a potential target of
RT   the LAZ-3/BCL-6 oncogene.";
RL   Oncogene 18:365-375(1999).
RN   [6]
RP   FUNCTION, INTERACTION WITH SP1, AND DOMAIN.
RX   PubMed=12004059; DOI=10.1074/jbc.m202078200;
RA   Lee D.K., Suh D., Edenberg H.J., Hur M.W.;
RT   "POZ domain transcription factor, FBI-1, represses transcription of
RT   ADH5/FDH by interacting with the zinc finger and interfering with DNA
RT   binding activity of Sp1.";
RL   J. Biol. Chem. 277:26761-26768(2002).
RN   [7]
RP   FUNCTION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=14701838; DOI=10.1074/jbc.m310240200;
RA   Laudes M., Christodoulides C., Sewter C., Rochford J.J., Considine R.V.,
RA   Sethi J.K., Vidal-Puig A., O'Rahilly S.;
RT   "Role of the POZ zinc finger transcription factor FBI-1 in human and murine
RT   adipogenesis.";
RL   J. Biol. Chem. 279:11711-11718(2004).
RN   [8]
RP   TISSUE SPECIFICITY.
RX   PubMed=15662416; DOI=10.1038/nature03203;
RA   Maeda T., Hobbs R.M., Merghoub T., Guernah I., Zelent A., Cordon-Cardo C.,
RA   Teruya-Feldstein J., Pandolfi P.P.;
RT   "Role of the proto-oncogene Pokemon in cellular transformation and ARF
RT   repression.";
RL   Nature 433:278-285(2005).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-337 AND SER-549, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, SUMOYLATION, AND MUTAGENESIS OF LYS-61;
RP   LYS-354; LYS-371; LYS-379; LYS-383; LYS-396; LYS-486; LYS-487; LYS-536 AND
RP   LYS-539.
RX   PubMed=17595526; DOI=10.1159/000104164;
RA   Roh H.E., Lee M.N., Jeon B.N., Choi W.I., Kim Y.J., Yu M.Y., Hur M.W.;
RT   "Regulation of pokemon 1 activity by sumoylation.";
RL   Cell. Physiol. Biochem. 20:167-180(2007).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-526, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-511 AND SER-525, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-337; SER-341 AND SER-549, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [16]
RP   FUNCTION, INTERACTION WITH AR; NCOR1 AND NCOR2, AND DOMAIN.
RX   PubMed=20812024; DOI=10.1007/s00018-010-0511-7;
RA   Cui J., Yang Y., Zhang C., Hu P., Kan W., Bai X., Liu X., Song H.;
RT   "FBI-1 functions as a novel AR co-repressor in prostate cancer cells.";
RL   Cell. Mol. Life Sci. 68:1091-1103(2011).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-337 AND SER-549, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [18]
RP   FUNCTION, INTERACTION WITH KHDRBS1, SUBCELLULAR LOCATION, AND REGION.
RX   PubMed=24514149; DOI=10.1002/embr.201338241;
RA   Bielli P., Busa R., Di Stasi S.M., Munoz M.J., Botti F., Kornblihtt A.R.,
RA   Sette C.;
RT   "The transcription factor FBI-1 inhibits SAM68-mediated BCL-X alternative
RT   splicing and apoptosis.";
RL   EMBO Rep. 15:419-427(2014).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-337 AND SER-549, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [20]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-539, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [21]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-539, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [22]
RP   FUNCTION, INTERACTION WITH HDAC1 AND SMAD4, DOMAIN, AND REGION.
RX   PubMed=25514493; DOI=10.1016/j.bbagrm.2014.12.008;
RA   Yang Y., Cui J., Xue F., Zhang C., Mei Z., Wang Y., Bi M., Shan D.,
RA   Meredith A., Li H., Xu Z.Q.;
RT   "Pokemon (FBI-1) interacts with Smad4 to repress TGF-beta-induced
RT   transcriptional responses.";
RL   Biochim. Biophys. Acta 1849:270-281(2015).
RN   [23]
RP   INTERACTION WITH THE DNA-DEPENDENT PROTEIN KINASE COMPLEX.
RX   PubMed=26446488; DOI=10.1038/ncomms9325;
RA   Liu X.S., Chandramouly G., Rass E., Guan Y., Wang G., Hobbs R.M.,
RA   Rajendran A., Xie A., Shah J.V., Davis A.J., Scully R., Lunardi A.,
RA   Pandolfi P.P.;
RT   "LRF maintains genome integrity by regulating the non-homologous end
RT   joining pathway of DNA repair.";
RL   Nat. Commun. 6:8325-8325(2015).
RN   [24]
RP   FUNCTION, AND MUTAGENESIS OF PRO-14; SER-22; ARG-49; LYS-60; ASP-78;
RP   ARG-112; PRO-184; GLN-322; SER-326; SER-357; ARG-377; CYS-387; ILE-391;
RP   ARG-399; ARG-402; THR-403; HIS-404; GLY-406; PRO-409; CYS-412; LYS-424;
RP   ARG-430; THR-461; LEU-463; TYR-466; ALA-522; GLU-541; GLY-562 AND ASP-576.
RX   PubMed=26455326; DOI=10.1038/onc.2015.371;
RA   Liu X.S., Liu Z., Gerarduzzi C., Choi D.E., Ganapathy S., Pandolfi P.P.,
RA   Yuan Z.M.;
RT   "Somatic human ZBTB7A zinc finger mutations promote cancer progression.";
RL   Oncogene 35:3071-3078(2016).
RN   [25]
RP   FUNCTION, AND DEVELOPMENTAL STAGE.
RX   PubMed=26816381; DOI=10.1126/science.aad3312;
RA   Masuda T., Wang X., Maeda M., Canver M.C., Sher F., Funnell A.P.,
RA   Fisher C., Suciu M., Martyn G.E., Norton L.J., Zhu C., Kurita R.,
RA   Nakamura Y., Xu J., Higgs D.R., Crossley M., Bauer D.E., Orkin S.H.,
RA   Kharchenko P.V., Maeda T.;
RT   "Transcription factors LRF and BCL11A independently repress expression of
RT   fetal hemoglobin.";
RL   Science 351:285-289(2016).
RN   [26]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-436 AND LYS-539, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [27]
RP   INTERACTION WITH RELA.
RX   PubMed=29813070; DOI=10.1371/journal.pbio.2004526;
RA   Ramos Pittol J.M., Oruba A., Mittler G., Saccani S., van Essen D.;
RT   "Zbtb7a is a transducer for the control of promoter accessibility by NF-
RT   kappa B and multiple other transcription factors.";
RL   PLoS Biol. 16:E2004526-E2004526(2018).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 9-128.
RX   PubMed=17052694; DOI=10.1016/j.bbrc.2006.09.167;
RA   Schubot F.D., Tropea J.E., Waugh D.S.;
RT   "Structure of the POZ domain of human LRF, a master regulator of
RT   oncogenesis.";
RL   Biochem. Biophys. Res. Commun. 351:1-6(2006).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1-131.
RX   PubMed=17189472; DOI=10.1110/ps.062660907;
RA   Stogios P.J., Chen L., Prive G.G.;
RT   "Crystal structure of the BTB domain from the LRF/ZBTB7 transcriptional
RT   regulator.";
RL   Protein Sci. 16:336-342(2007).
RN   [30]
RP   VARIANT MNDLFH TRP-384, AND INVOLVEMENT IN MNDLFH.
RX   PubMed=31645653; DOI=10.1038/s10038-019-0690-5;
RA   Ohishi A., Masunaga Y., Iijima S., Yamoto K., Kato F., Fukami M.,
RA   Saitsu H., Ogata T.;
RT   "De novo ZBTB7A variant in a patient with macrocephaly, intellectual
RT   disability, and sleep apnea: implications for the phenotypic development in
RT   19p13.3 microdeletions.";
RL   J. Hum. Genet. 65:181-186(2020).
RN   [31]
RP   VARIANTS MNDLFH ILE-56; 278-GLU--ALA-584 DEL; 370-GLN--ALA-584 DEL; LYS-405
RP   AND ASN-452, AND INVOLVEMENT IN MNDLFH.
RX   PubMed=34515416; DOI=10.1002/ajmg.a.62492;
RA   von der Lippe C., Tveten K., Prescott T.E., Holla O.L., Busk O.L.,
RA   Burke K.B., Sansbury F.H., Baptista J., Fry A.E., Lim D., Jolles S.,
RA   Evans J., Osio D., Macmillan C., Bruno I., Faletra F., Climent S.,
RA   Urreitzi R., Hoenicka J., Palau F., Cohen A.S.A., Engleman K., Zhou D.,
RA   Amudhavalli S.M., Jeanne M., Bonnet-Brilhault F., Levy J., Drunat S.,
RA   Derive N., Haug M.G., Thorstensen W.M.;
RT   "Heterozygous variants in ZBTB7A cause a neurodevelopmental disorder
RT   associated with symptomatic overgrowth of pharyngeal lymphoid tissue,
RT   macrocephaly, and elevated fetal hemoglobin.";
RL   Am. J. Med. Genet. A 188:272-282(2022).
CC   -!- FUNCTION: Transcription factor that represses the transcription of a
CC       wide range of genes involved in cell proliferation and differentiation
CC       (PubMed:14701838, PubMed:17595526, PubMed:20812024, PubMed:25514493,
CC       PubMed:26455326, PubMed:26816381). Directly and specifically binds to
CC       the consensus sequence 5'-[GA][CA]GACCCCCCCCC-3' and represses
CC       transcription both by regulating the organization of chromatin and
CC       through the direct recruitment of transcription factors to gene
CC       regulatory regions (PubMed:12004059, PubMed:17595526, PubMed:20812024,
CC       PubMed:25514493, PubMed:26816381). Negatively regulates SMAD4
CC       transcriptional activity in the TGF-beta signaling pathway through
CC       these two mechanisms (PubMed:25514493). That is, recruits the chromatin
CC       regulator HDAC1 to the SMAD4-DNA complex and in parallel prevents the
CC       recruitment of the transcriptional activators CREBBP and EP300
CC       (PubMed:25514493). Collaborates with transcription factors like RELA to
CC       modify the accessibility of gene transcription regulatory regions to
CC       secondary transcription factors (By similarity). Also directly
CC       interacts with transcription factors like SP1 to prevent their binding
CC       to DNA (PubMed:12004059). Functions as an androgen receptor/AR
CC       transcriptional corepressor by recruiting NCOR1 and NCOR2 to the
CC       androgen response elements/ARE on target genes (PubMed:20812024).
CC       Thereby, negatively regulates androgen receptor signaling and androgen-
CC       induced cell proliferation (PubMed:20812024). Involved in the switch
CC       between fetal and adult globin expression during erythroid cells
CC       maturation (PubMed:26816381). Through its interaction with the NuRD
CC       complex regulates chromatin at the fetal globin genes to repress their
CC       transcription (PubMed:26816381). Specifically represses the
CC       transcription of the tumor suppressor ARF isoform from the CDKN2A gene
CC       (By similarity). Efficiently abrogates E2F1-dependent CDKN2A
CC       transactivation (By similarity). Regulates chondrogenesis through the
CC       transcriptional repression of specific genes via a mechanism that also
CC       requires histone deacetylation (By similarity). Regulates cell
CC       proliferation through the transcriptional regulation of genes involved
CC       in glycolysis (PubMed:26455326). Involved in adipogenesis through the
CC       regulation of genes involved in adipocyte differentiation
CC       (PubMed:14701838). Plays a key role in the differentiation of lymphoid
CC       progenitors into B and T lineages (By similarity). Promotes
CC       differentiation towards the B lineage by inhibiting the T-cell
CC       instructive Notch signaling pathway through the specific
CC       transcriptional repression of Notch downstream target genes (By
CC       similarity). Also regulates osteoclast differentiation (By similarity).
CC       May also play a role, independently of its transcriptional activity, in
CC       double-strand break repair via classical non-homologous end
CC       joining/cNHEJ (By similarity). Recruited to double-strand break sites
CC       on damage DNA, interacts with the DNA-dependent protein kinase complex
CC       and directly regulates its stability and activity in DNA repair (By
CC       similarity). May also modulate the splicing activity of KHDRBS1 toward
CC       BCL2L1 in a mechanism which is histone deacetylase-dependent and
CC       thereby negatively regulates the pro-apoptotic effect of KHDRBS1
CC       (PubMed:24514149). {ECO:0000250|UniProtKB:O88939,
CC       ECO:0000250|UniProtKB:Q9QZ48, ECO:0000269|PubMed:12004059,
CC       ECO:0000269|PubMed:14701838, ECO:0000269|PubMed:17595526,
CC       ECO:0000269|PubMed:20812024, ECO:0000269|PubMed:24514149,
CC       ECO:0000269|PubMed:25514493, ECO:0000269|PubMed:26455326,
CC       ECO:0000269|PubMed:26816381}.
CC   -!- SUBUNIT: Homodimer (PubMed:9973611). Interacts with BCL6 (By
CC       similarity). Interacts with RELA; involved in the control by RELA of
CC       the accessibility of target gene promoters (PubMed:29813070). Interacts
CC       with AR (via NR LBD domain); the interaction is direct and androgen-
CC       dependent (PubMed:20812024). Interacts with NCOR1 (PubMed:20812024).
CC       Interacts with NCOR2 (PubMed:20812024). Interacts with SMAD4; the
CC       interaction is direct and stimulated by TGFB1 (PubMed:25514493).
CC       Interacts with HDAC1 (PubMed:25514493). Interacts with SP1; ZBTB7A
CC       prevents the binding to GC-rich motifs in promoters and represses the
CC       transcriptional activity of SP1 (PubMed:12004059). Interacts with the
CC       DNA-dependent protein kinase complex/DNA-PKc (PubMed:26446488).
CC       Interacts with KHDRBS1; negatively regulates KHDRBS1 splicing activity
CC       (PubMed:24514149). {ECO:0000250|UniProtKB:O88939,
CC       ECO:0000269|PubMed:12004059, ECO:0000269|PubMed:20812024,
CC       ECO:0000269|PubMed:24514149, ECO:0000269|PubMed:25514493,
CC       ECO:0000269|PubMed:26446488, ECO:0000269|PubMed:29813070,
CC       ECO:0000269|PubMed:9973611}.
CC   -!- INTERACTION:
CC       O95365; Q9NRL2: BAZ1A; NbExp=2; IntAct=EBI-2795384, EBI-927511;
CC       O95365; Q12873: CHD3; NbExp=2; IntAct=EBI-2795384, EBI-523590;
CC       O95365; Q9HCK8: CHD8; NbExp=2; IntAct=EBI-2795384, EBI-1169146;
CC       O95365; Q8WXI9: GATAD2B; NbExp=4; IntAct=EBI-2795384, EBI-923440;
CC       O95365; Q13547: HDAC1; NbExp=2; IntAct=EBI-2795384, EBI-301834;
CC       O95365; Q8IX15-3: HOMEZ; NbExp=3; IntAct=EBI-2795384, EBI-10172004;
CC       O95365; Q07666: KHDRBS1; NbExp=9; IntAct=EBI-2795384, EBI-1364;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:17595526,
CC       ECO:0000269|PubMed:24514149}. Note=Recruited to double-strand break
CC       sites of damaged DNA. {ECO:0000250|UniProtKB:O88939}.
CC   -!- TISSUE SPECIFICITY: Widely expressed (PubMed:9927193). In normal
CC       thymus, expressed in medullary epithelial cells and Hassle's corpuscles
CC       (at protein level) (PubMed:15662416). In tonsil, expressed in squamous
CC       epithelium and germinal center lymphocytes (at protein level)
CC       (PubMed:15662416). Up-regulated in a subset of lymphomas, as well as in
CC       a subset of breast, lung, colon, prostate and bladder carcinomas (at
CC       protein level) (PubMed:15662416). Expressed in adipose tissues
CC       (PubMed:14701838). {ECO:0000269|PubMed:14701838,
CC       ECO:0000269|PubMed:15662416, ECO:0000269|PubMed:9927193}.
CC   -!- DEVELOPMENTAL STAGE: Expression is increased in differentiating
CC       erythroid cells (at protein level) (PubMed:26816381). Up-regulated
CC       during adipocyte differentiation (PubMed:14701838).
CC       {ECO:0000269|PubMed:14701838, ECO:0000269|PubMed:26816381}.
CC   -!- DOMAIN: The BTB domain mediates the interaction with the androgen
CC       receptor/AR and HDAC1 (PubMed:20812024, PubMed:25514493). Also mediates
CC       the interaction with SP1 (PubMed:12004059).
CC       {ECO:0000269|PubMed:12004059, ECO:0000269|PubMed:20812024,
CC       ECO:0000269|PubMed:25514493}.
CC   -!- PTM: Sumoylated. Undergoes sumoylation with SUMO1 that may regulate its
CC       transcriptional activity. {ECO:0000269|PubMed:17595526}.
CC   -!- DISEASE: Macrocephaly, neurodevelopmental delay, lymphoid hyperplasia,
CC       and persistent fetal hemoglobin (MNDLFH) [MIM:619769]: An autosomal
CC       dominant disease characterized by pharyngeal lymphoid hypertrophy, with
CC       adenoid overgrowth, sleep apnea, macrocephaly without structural brain
CC       abnormalities, and impaired intellectual development. An increased
CC       fraction of fetal hemoglobin has been observed in some patients.
CC       {ECO:0000269|PubMed:31645653, ECO:0000269|PubMed:34515416}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB58414.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/42863/ZBTB7A";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF097916; AAC72973.1; -; mRNA.
DR   EMBL; AF000561; AAB58414.1; ALT_FRAME; mRNA.
DR   EMBL; CH471139; EAW69267.1; -; Genomic_DNA.
DR   EMBL; CH471139; EAW69268.1; -; Genomic_DNA.
DR   EMBL; CH471139; EAW69270.1; -; Genomic_DNA.
DR   EMBL; CH471139; EAW69271.1; -; Genomic_DNA.
DR   EMBL; CH471139; EAW69272.1; -; Genomic_DNA.
DR   EMBL; BC084568; AAH84568.1; -; mRNA.
DR   EMBL; BC113511; AAI13512.1; -; mRNA.
DR   CCDS; CCDS12119.1; -.
DR   RefSeq; NP_001304919.1; NM_001317990.1.
DR   RefSeq; NP_056982.1; NM_015898.3.
DR   RefSeq; XP_005259628.1; XM_005259571.4.
DR   PDB; 2IF5; X-ray; 2.00 A; A=9-128.
DR   PDB; 2NN2; X-ray; 2.10 A; A/B=1-131.
DR   PDB; 7EYI; X-ray; 2.40 A; G/H=382-506.
DR   PDB; 7N5S; X-ray; 2.86 A; A=369-500.
DR   PDB; 7N5T; X-ray; 2.90 A; A=369-500.
DR   PDB; 7N5U; X-ray; 2.86 A; A=369-500.
DR   PDB; 7N5V; X-ray; 3.08 A; A/B/F=369-500.
DR   PDB; 7N5W; X-ray; 2.24 A; A=380-500.
DR   PDB; 8E3D; X-ray; 2.62 A; A/B/F=380-500.
DR   PDB; 8E3E; X-ray; 2.99 A; A/B/F=341-505.
DR   PDBsum; 2IF5; -.
DR   PDBsum; 2NN2; -.
DR   PDBsum; 7EYI; -.
DR   PDBsum; 7N5S; -.
DR   PDBsum; 7N5T; -.
DR   PDBsum; 7N5U; -.
DR   PDBsum; 7N5V; -.
DR   PDBsum; 7N5W; -.
DR   PDBsum; 8E3D; -.
DR   PDBsum; 8E3E; -.
DR   AlphaFoldDB; O95365; -.
DR   SMR; O95365; -.
DR   BioGRID; 119488; 131.
DR   DIP; DIP-56307N; -.
DR   IntAct; O95365; 18.
DR   MINT; O95365; -.
DR   STRING; 9606.ENSP00000323670; -.
DR   ChEMBL; CHEMBL5069375; -.
DR   iPTMnet; O95365; -.
DR   PhosphoSitePlus; O95365; -.
DR   SwissPalm; O95365; -.
DR   BioMuta; ZBTB7A; -.
DR   EPD; O95365; -.
DR   jPOST; O95365; -.
DR   MassIVE; O95365; -.
DR   MaxQB; O95365; -.
DR   PaxDb; O95365; -.
DR   PeptideAtlas; O95365; -.
DR   ProteomicsDB; 50825; -.
DR   Antibodypedia; 11338; 399 antibodies from 39 providers.
DR   DNASU; 51341; -.
DR   Ensembl; ENST00000322357.9; ENSP00000323670.3; ENSG00000178951.9.
DR   Ensembl; ENST00000601588.1; ENSP00000471865.1; ENSG00000178951.9.
DR   GeneID; 51341; -.
DR   KEGG; hsa:51341; -.
DR   MANE-Select; ENST00000322357.9; ENSP00000323670.3; NM_015898.4; NP_056982.1.
DR   UCSC; uc002lzh.4; human.
DR   AGR; HGNC:18078; -.
DR   CTD; 51341; -.
DR   DisGeNET; 51341; -.
DR   GeneCards; ZBTB7A; -.
DR   HGNC; HGNC:18078; ZBTB7A.
DR   HPA; ENSG00000178951; Low tissue specificity.
DR   MalaCards; ZBTB7A; -.
DR   MIM; 605878; gene.
DR   MIM; 619769; phenotype.
DR   neXtProt; NX_O95365; -.
DR   OpenTargets; ENSG00000178951; -.
DR   PharmGKB; PA134885165; -.
DR   VEuPathDB; HostDB:ENSG00000178951; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   GeneTree; ENSGT00940000162053; -.
DR   HOGENOM; CLU_025627_1_0_1; -.
DR   InParanoid; O95365; -.
DR   OMA; MRRCQDQ; -.
DR   OrthoDB; 783166at2759; -.
DR   PhylomeDB; O95365; -.
DR   TreeFam; TF331824; -.
DR   PathwayCommons; O95365; -.
DR   SignaLink; O95365; -.
DR   SIGNOR; O95365; -.
DR   BioGRID-ORCS; 51341; 222 hits in 1236 CRISPR screens.
DR   ChiTaRS; ZBTB7A; human.
DR   EvolutionaryTrace; O95365; -.
DR   GeneWiki; ZBTB7A; -.
DR   GenomeRNAi; 51341; -.
DR   Pharos; O95365; Tbio.
DR   PRO; PR:O95365; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; O95365; protein.
DR   Bgee; ENSG00000178951; Expressed in buccal mucosa cell and 201 other tissues.
DR   Genevisible; O95365; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0070418; C:DNA-dependent protein kinase complex; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0035861; C:site of double-strand break; IEA:Ensembl.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IBA:GO_Central.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IEA:Ensembl.
DR   GO; GO:0035035; F:histone acetyltransferase binding; ISS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0050681; F:nuclear androgen receptor binding; IDA:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IMP:UniProtKB.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0046332; F:SMAD binding; IDA:UniProtKB.
DR   GO; GO:0001222; F:transcription corepressor binding; IDA:UniProtKB.
DR   GO; GO:0030183; P:B cell differentiation; ISS:UniProtKB.
DR   GO; GO:0006325; P:chromatin organization; ISS:UniProtKB.
DR   GO; GO:0006338; P:chromatin remodeling; IMP:UniProtKB.
DR   GO; GO:0097680; P:double-strand break repair via classical nonhomologous end joining; ISS:UniProtKB.
DR   GO; GO:0043249; P:erythrocyte maturation; IMP:UniProtKB.
DR   GO; GO:0045444; P:fat cell differentiation; IMP:UniProtKB.
DR   GO; GO:0060766; P:negative regulation of androgen receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0045746; P:negative regulation of Notch signaling pathway; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:UniProtKB.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0034504; P:protein localization to nucleus; IMP:UniProtKB.
DR   GO; GO:0000381; P:regulation of alternative mRNA splicing, via spliceosome; IDA:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0051090; P:regulation of DNA-binding transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0006110; P:regulation of glycolytic process; IMP:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:GO_Central.
DR   GO; GO:2000677; P:regulation of transcription regulatory region DNA binding; IDA:UniProtKB.
DR   CDD; cd18326; BTB_POZ_ZBTB7A; 1.
DR   Gene3D; 3.30.160.60; Classic Zinc Finger; 4.
DR   InterPro; IPR000210; BTB/POZ_dom.
DR   InterPro; IPR011333; SKP1/BTB/POZ_sf.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   PANTHER; PTHR46105; AGAP004733-PA; 1.
DR   PANTHER; PTHR46105:SF6; ZINC FINGER AND BTB DOMAIN-CONTAINING PROTEIN 7A; 1.
DR   Pfam; PF00651; BTB; 1.
DR   Pfam; PF00096; zf-C2H2; 2.
DR   SMART; SM00225; BTB; 1.
DR   SMART; SM00355; ZnF_C2H2; 4.
DR   SUPFAM; SSF57667; beta-beta-alpha zinc fingers; 2.
DR   SUPFAM; SSF54695; POZ domain; 1.
DR   PROSITE; PS50097; BTB; 1.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 3.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 4.
PE   1: Evidence at protein level;
KW   3D-structure; Developmental protein; Differentiation; Disease variant;
KW   DNA-binding; Intellectual disability; Isopeptide bond; Metal-binding;
KW   Nucleus; Phosphoprotein; Reference proteome; Repeat; Repressor;
KW   Transcription; Transcription regulation; Ubl conjugation; Zinc;
KW   Zinc-finger.
FT   CHAIN           1..584
FT                   /note="Zinc finger and BTB domain-containing protein 7A"
FT                   /id="PRO_0000047715"
FT   DOMAIN          34..101
FT                   /note="BTB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00037"
FT   ZN_FING         382..404
FT                   /note="C2H2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         410..432
FT                   /note="C2H2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         438..460
FT                   /note="C2H2-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         466..490
FT                   /note="C2H2-type 4; atypical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   REGION          220..313
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          277..584
FT                   /note="Mediates interaction with KHDRBS1"
FT                   /evidence="ECO:0000269|PubMed:24514149"
FT   REGION          349..584
FT                   /note="Mediates interaction with RELA"
FT                   /evidence="ECO:0000250|UniProtKB:O88939"
FT   REGION          377..584
FT                   /note="Mediates interaction with SMAD4"
FT                   /evidence="ECO:0000269|PubMed:25514493"
FT   REGION          486..584
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         337
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         341
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         511
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         525
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         526
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         549
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   CROSSLNK        436
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        539
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:28112733"
FT   VARIANT         56
FT                   /note="S -> I (in MNDLFH; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:34515416"
FT                   /id="VAR_086968"
FT   VARIANT         278..584
FT                   /note="Missing (in MNDLFH)"
FT                   /evidence="ECO:0000269|PubMed:34515416"
FT                   /id="VAR_086969"
FT   VARIANT         370..584
FT                   /note="Missing (in MNDLFH)"
FT                   /evidence="ECO:0000269|PubMed:34515416"
FT                   /id="VAR_086970"
FT   VARIANT         384
FT                   /note="C -> W (in MNDLFH)"
FT                   /evidence="ECO:0000269|PubMed:31645653"
FT                   /id="VAR_086971"
FT   VARIANT         405
FT                   /note="T -> K (in MNDLFH)"
FT                   /evidence="ECO:0000269|PubMed:34515416"
FT                   /id="VAR_086972"
FT   VARIANT         452
FT                   /note="D -> N (in MNDLFH; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:34515416"
FT                   /id="VAR_086973"
FT   MUTAGEN         14
FT                   /note="P->S: No effect on transcription repressor activity.
FT                   No effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         22
FT                   /note="S->R: No effect on transcription repressor activity.
FT                   No effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         49
FT                   /note="R->H: Increased proteasomal degradation. No effect
FT                   on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         60
FT                   /note="K->R: No effect on transcription repressor activity.
FT                   No effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         61
FT                   /note="K->R: Loss of sumoylation with SUMO1. May decrease
FT                   interaction with transcriptional corepressors."
FT                   /evidence="ECO:0000269|PubMed:17595526"
FT   MUTAGEN         78
FT                   /note="D->E: No effect on transcription repressor activity.
FT                   No effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         112
FT                   /note="R->C: No effect on transcription repressor activity.
FT                   No effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         184
FT                   /note="P->S: Decreased transcription repressor activity. No
FT                   effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         322
FT                   /note="Q->L: Decreased transcription repressor activity. No
FT                   effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         326
FT                   /note="S->R: No effect on transcription repressor activity.
FT                   No effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         354
FT                   /note="K->R: No effect on sumoylation with SUMO1. No effect
FT                   on promoter binding."
FT                   /evidence="ECO:0000269|PubMed:17595526"
FT   MUTAGEN         357
FT                   /note="S->R: No effect on transcription repressor activity.
FT                   No effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         371
FT                   /note="K->R: No effect on sumoylation with SUMO1. No effect
FT                   on promoter binding."
FT                   /evidence="ECO:0000269|PubMed:17595526"
FT   MUTAGEN         377
FT                   /note="R->L: No effect on transcription repressor activity.
FT                   No effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         379
FT                   /note="K->R: No effect on sumoylation with SUMO1. Decreased
FT                   transcription repression activity. No effect on promoter
FT                   binding."
FT                   /evidence="ECO:0000269|PubMed:17595526"
FT   MUTAGEN         383
FT                   /note="K->R: No effect on sumoylation with SUMO1. No effect
FT                   on promoter binding."
FT                   /evidence="ECO:0000269|PubMed:17595526"
FT   MUTAGEN         387
FT                   /note="C->F: Decreased transcription repressor activity. No
FT                   effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         391
FT                   /note="I->L: No effect on transcription repressor activity.
FT                   No effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         396
FT                   /note="K->R: No effect on sumoylation with SUMO1. Decreased
FT                   transcription repression activity. No effect on promoter
FT                   binding."
FT                   /evidence="ECO:0000269|PubMed:17595526"
FT   MUTAGEN         399
FT                   /note="R->L: Decreased transcription repressor activity,
FT                   dominant negative effect. Increased glycolysis and cell
FT                   proliferation, dominant negative effect. No effect on
FT                   nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         402
FT                   /note="R->H: Decreased transcription repressor activity.
FT                   Acts as a dominant negative. No effect on nuclear
FT                   localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         403
FT                   /note="T->N: Decreased transcription repressor activity. No
FT                   effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         404
FT                   /note="H->R: Decreased transcription repressor activity.
FT                   Acts as a dominant negative. No effect on nuclear
FT                   localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         406
FT                   /note="G->V: Decreased transcription repressor activity. No
FT                   effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         409
FT                   /note="P->S: Decreased transcription repressor activity. No
FT                   effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         412
FT                   /note="C->Y: Decreased transcription repressor activity. No
FT                   effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         424
FT                   /note="K->N: Decreased transcription repressor activity. No
FT                   effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         424
FT                   /note="K->T: No effect on transcription repressor activity.
FT                   No effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         430
FT                   /note="R->W: Decreased transcription repressor activity. No
FT                   effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         461
FT                   /note="T->M: No effect on transcription repressor activity.
FT                   No effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         463
FT                   /note="L->M: No effect on transcription repressor activity.
FT                   No effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         466
FT                   /note="Y->D: Decreased transcription repressor activity. No
FT                   effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         486
FT                   /note="K->R: No effect on sumoylation with SUMO1. No effect
FT                   on promoter binding. No effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:17595526"
FT   MUTAGEN         487
FT                   /note="K->R: No effect on sumoylation with SUMO1. No effect
FT                   on promoter binding. No effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:17595526"
FT   MUTAGEN         522
FT                   /note="A->T: No effect on transcription repressor activity.
FT                   No effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         536
FT                   /note="K->R: No effect on sumoylation with SUMO1. Decreased
FT                   transcription repression activity. No effect on promoter
FT                   binding."
FT                   /evidence="ECO:0000269|PubMed:17595526"
FT   MUTAGEN         539
FT                   /note="K->R: No effect on sumoylation with SUMO1. Decreased
FT                   transcription repression activity. No effect on promoter
FT                   binding."
FT                   /evidence="ECO:0000269|PubMed:17595526"
FT   MUTAGEN         541
FT                   /note="E->K: No effect on transcription repressor activity.
FT                   No effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         562
FT                   /note="G->D: No effect on transcription repressor activity.
FT                   No effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   MUTAGEN         576
FT                   /note="D->V: No effect on transcription repressor activity.
FT                   No effect on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26455326"
FT   CONFLICT        554
FT                   /note="G -> C (in Ref. 4; AAH84568)"
FT                   /evidence="ECO:0000305"
FT   STRAND          9..12
FT                   /evidence="ECO:0007829|PDB:2NN2"
FT   HELIX           16..29
FT                   /evidence="ECO:0007829|PDB:2IF5"
FT   STRAND          36..40
FT                   /evidence="ECO:0007829|PDB:2IF5"
FT   STRAND          43..47
FT                   /evidence="ECO:0007829|PDB:2IF5"
FT   HELIX           49..55
FT                   /evidence="ECO:0007829|PDB:2IF5"
FT   HELIX           57..64
FT                   /evidence="ECO:0007829|PDB:2IF5"
FT   STRAND          73..76
FT                   /evidence="ECO:0007829|PDB:2IF5"
FT   HELIX           82..94
FT                   /evidence="ECO:0007829|PDB:2IF5"
FT   STRAND          95..99
FT                   /evidence="ECO:0007829|PDB:2NN2"
FT   HELIX           101..103
FT                   /evidence="ECO:0007829|PDB:2IF5"
FT   HELIX           104..113
FT                   /evidence="ECO:0007829|PDB:2IF5"
FT   HELIX           117..127
FT                   /evidence="ECO:0007829|PDB:2IF5"
FT   TURN            385..387
FT                   /evidence="ECO:0007829|PDB:7EYI"
FT   STRAND          390..393
FT                   /evidence="ECO:0007829|PDB:7EYI"
FT   HELIX           394..396
FT                   /evidence="ECO:0007829|PDB:7N5S"
FT   HELIX           397..405
FT                   /evidence="ECO:0007829|PDB:7EYI"
FT   STRAND          413..415
FT                   /evidence="ECO:0007829|PDB:7EYI"
FT   STRAND          418..420
FT                   /evidence="ECO:0007829|PDB:7EYI"
FT   HELIX           422..433
FT                   /evidence="ECO:0007829|PDB:7EYI"
FT   TURN            441..443
FT                   /evidence="ECO:0007829|PDB:7EYI"
FT   STRAND          446..449
FT                   /evidence="ECO:0007829|PDB:7EYI"
FT   HELIX           450..461
FT                   /evidence="ECO:0007829|PDB:7EYI"
FT   TURN            469..471
FT                   /evidence="ECO:0007829|PDB:7EYI"
FT   STRAND          474..477
FT                   /evidence="ECO:0007829|PDB:7EYI"
FT   HELIX           478..486
FT                   /evidence="ECO:0007829|PDB:7EYI"
SQ   SEQUENCE   584 AA;  61439 MW;  50073663F3D393A0 CRC64;
     MAGGVDGPIG IPFPDHSSDI LSGLNEQRTQ GLLCDVVILV EGREFPTHRS VLAACSQYFK
     KLFTSGAVVD QQNVYEIDFV SAEALTALMD FAYTATLTVS TANVGDILSA ARLLEIPAVS
     HVCADLLDRQ ILAADAGADA GQLDLVDQID QRNLLRAKEY LEFFQSNPMN SLPPAAAAAA
     ASFPWSAFGA SDDDLDATKE AVAAAVAAVA AGDCNGLDFY GPGPPAERPP TGDGDEGDSN
     PGLWPERDED APTGGLFPPP VAPPAATQNG HYGRGGEEEA ASLSEAAPEP GDSPGFLSGA
     AEGEDGDGPD VDGLAASTLL QQMMSSVGRA GAAAGDSDEE SRADDKGVMD YYLKYFSGAH
     DGDVYPAWSQ KVEKKIRAKA FQKCPICEKV IQGAGKLPRH IRTHTGEKPY ECNICKVRFT
     RQDKLKVHMR KHTGEKPYLC QQCGAAFAHN YDLKNHMRVH TGLRPYQCDS CCKTFVRSDH
     LHRHLKKDGC NGVPSRRGRK PRVRGGAPDP SPGATATPGA PAQPSSPDAR RNGQEKHFKD
     EDEDEDVASP DGLGRLNVAG AGGGGDSGGG PGAATDGNFT AGLA
//
